204
M. Irfan et al.
84. Biroccio A, Hamm J, Incitti I, De Francesco R, Tomei L (2002) Selection of RNA aptamers that
are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase.
J Virol 76(8):3688–3696
85. Bellecave P, Cazenave C, Rumi J, Staedel C, Cosnefroy O, Andreola M-L, Ventura M, TarragoLitvak L, Astier-Gin T (2008) Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA
aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells.
Antimicrob Agents Chemother 52(6):2097–2110
86. Zhang Z, Zhang J, Pei X, Zhang Q, Lu B, Zhang X, Liu J (2014) An aptamer targets HBV core
protein and suppresses HBV replication in HepG2. 2.15 cells. Int J Mol Med 34(5):1423–1429
87. Roseman AM, Berriman JA, Wynne SA, Butler PJG, Crowther RA (2005) A structural model
for maturation of the hepatitis B virus core. Proc Natl Acad Sci 102(44):15821–15826
88. Butz K, Denk C, Fitscher B, Crnkovic-Mertens I, Ullmann A, Schröder CH, Hoppe-Seyler F
(2001) Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules
with antiviral activity. Oncogene 20(45):6579–6586
89. Kim SJ, Kim MY, Lee JH, You JC, Jeong S (2002) Selection and stabilization of the RNA
aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem
Biophys Res Commun 291(4):925–931
90. Lever AM (2007) HIV-1 RNA Packaging. Adv Pharmacol 55:1–32
91. Jang KJ, Lee N-R, Yeo W-S, Jeong Y-J, Kim D-E (2008) Isolation of inhibitory RNA aptamers
against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem
Biophys Res Commun 366(3):738–744
92. Zhou B, Wang B (2006) Pegaptanib for the treatment of age-related macular degeneration.
Exp Eye Res 83(3):615–619
93. Zhu S, Gilbert JC, Hatala P, Harvey W, Liang Z, Gao S, Kang D, Jilma B (2020) The development and characterization of a long acting anti-thrombotic von Willebrand Factor (VWF)
Aptamer. J Thromb Haemost 18(5):1113–1123
94. Nimjee SM, Sullenger BA (2020) Therapeutic aptamers: evolving to find their clinical niche.
Curr Med Chem 27(25):4181–4193
95. Becker R, Povsic T, Cohen MG, Rusconi C, Sullenger B (2010) Nucleic acid aptamers
as antithrombotic agents: opportunities in extracellular therapeutics. Thromb Haemost
103(03):586–595
96. Zhong W, Zhang Y, Tan W, Zhang J, Liu J, Wang G, Liao J, Liu B, Chen K, Yu B (2020)
Adipose specific aptamer adipo-8 recognizes and interacts with APMAP to ameliorates fat
deposition in vitro and in vivo. Life Sci 117609
97. Wang G, Liu J, Chen K, Xu Y, Liu B, Liao J, Zhu L, Hu X, Li J, Pu Y (2017) Selection
and characterization of DNA aptamer against glucagon receptor by cell-SELEX. Sci Rep
7(1):1–10
98. Ismail SI, Alshaer W (2018) Therapeutic aptamers in discovery, preclinical and clinical stages.
Adv Drug Deliv Rev 134:51–64
99. Chu TC, Twu KY, Ellington AD, Levy M (2006) Aptamer mediated siRNA delivery. Nucl
Acids Res 34(10):e73–e73
100. Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T (2008) Inhibition of polo-like kinase 1 by
blocking polo-box domain-dependent protein-protein interactions. Chem Biol 15(5):459–466
101. Willimott S, Wagner SD (2010) Post-transcriptional and post-translational regulation of Bcl2.
Portland Press Ltd
102. Min K, Jo H, Song K, Cho M, Chun Y-S, Jon S, Kim WJ, Ban C (2011) Dual-aptamerbased delivery vehicle of doxorubicin to both PSMA (+) and PSMA (−) prostate cancers.
Biomaterials 32(8):2124–2132
103. Zhu Q, Shibata T, Kabashima T, Kai M (2012) Inhibition of HIV-1 protease expression
in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur J Med Chem
56:396–399
104. Saini RK, Chouhan R, Bagri LP, Bajpai A (2012) Strategies of targeting tumors and cancers.
J Cancer Res Updat 1(1):129–152
M. Irfan et al.
84. Biroccio A, Hamm J, Incitti I, De Francesco R, Tomei L (2002) Selection of RNA aptamers that
are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase.
J Virol 76(8):3688–3696
85. Bellecave P, Cazenave C, Rumi J, Staedel C, Cosnefroy O, Andreola M-L, Ventura M, TarragoLitvak L, Astier-Gin T (2008) Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA
aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells.
Antimicrob Agents Chemother 52(6):2097–2110
86. Zhang Z, Zhang J, Pei X, Zhang Q, Lu B, Zhang X, Liu J (2014) An aptamer targets HBV core
protein and suppresses HBV replication in HepG2. 2.15 cells. Int J Mol Med 34(5):1423–1429
87. Roseman AM, Berriman JA, Wynne SA, Butler PJG, Crowther RA (2005) A structural model
for maturation of the hepatitis B virus core. Proc Natl Acad Sci 102(44):15821–15826
88. Butz K, Denk C, Fitscher B, Crnkovic-Mertens I, Ullmann A, Schröder CH, Hoppe-Seyler F
(2001) Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules
with antiviral activity. Oncogene 20(45):6579–6586
89. Kim SJ, Kim MY, Lee JH, You JC, Jeong S (2002) Selection and stabilization of the RNA
aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem
Biophys Res Commun 291(4):925–931
90. Lever AM (2007) HIV-1 RNA Packaging. Adv Pharmacol 55:1–32
91. Jang KJ, Lee N-R, Yeo W-S, Jeong Y-J, Kim D-E (2008) Isolation of inhibitory RNA aptamers
against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem
Biophys Res Commun 366(3):738–744
92. Zhou B, Wang B (2006) Pegaptanib for the treatment of age-related macular degeneration.
Exp Eye Res 83(3):615–619
93. Zhu S, Gilbert JC, Hatala P, Harvey W, Liang Z, Gao S, Kang D, Jilma B (2020) The development and characterization of a long acting anti-thrombotic von Willebrand Factor (VWF)
Aptamer. J Thromb Haemost 18(5):1113–1123
94. Nimjee SM, Sullenger BA (2020) Therapeutic aptamers: evolving to find their clinical niche.
Curr Med Chem 27(25):4181–4193
95. Becker R, Povsic T, Cohen MG, Rusconi C, Sullenger B (2010) Nucleic acid aptamers
as antithrombotic agents: opportunities in extracellular therapeutics. Thromb Haemost
103(03):586–595
96. Zhong W, Zhang Y, Tan W, Zhang J, Liu J, Wang G, Liao J, Liu B, Chen K, Yu B (2020)
Adipose specific aptamer adipo-8 recognizes and interacts with APMAP to ameliorates fat
deposition in vitro and in vivo. Life Sci 117609
97. Wang G, Liu J, Chen K, Xu Y, Liu B, Liao J, Zhu L, Hu X, Li J, Pu Y (2017) Selection
and characterization of DNA aptamer against glucagon receptor by cell-SELEX. Sci Rep
7(1):1–10
98. Ismail SI, Alshaer W (2018) Therapeutic aptamers in discovery, preclinical and clinical stages.
Adv Drug Deliv Rev 134:51–64
99. Chu TC, Twu KY, Ellington AD, Levy M (2006) Aptamer mediated siRNA delivery. Nucl
Acids Res 34(10):e73–e73
100. Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T (2008) Inhibition of polo-like kinase 1 by
blocking polo-box domain-dependent protein-protein interactions. Chem Biol 15(5):459–466
101. Willimott S, Wagner SD (2010) Post-transcriptional and post-translational regulation of Bcl2.
Portland Press Ltd
102. Min K, Jo H, Song K, Cho M, Chun Y-S, Jon S, Kim WJ, Ban C (2011) Dual-aptamerbased delivery vehicle of doxorubicin to both PSMA (+) and PSMA (−) prostate cancers.
Biomaterials 32(8):2124–2132
103. Zhu Q, Shibata T, Kabashima T, Kai M (2012) Inhibition of HIV-1 protease expression
in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur J Med Chem
56:396–399
104. Saini RK, Chouhan R, Bagri LP, Bajpai A (2012) Strategies of targeting tumors and cancers.
J Cancer Res Updat 1(1):129–152